ResMed Cash Flow Statement
NYSE: RMDHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ResMed free cash flow
In fiscal 2026, ResMed generated $1.81 billion of operating cash flow and spent $156.3 million on capital expenditures. That left free cash flow of $1.65 billion, a free-cash-flow margin of 29.2% of revenue. Free cash flow was down 0.7% from the prior year's $1.66 billion.
ResMed returned $1.05 billion to shareholders: $349.7 million in dividends and $700.0 million in share repurchases, equal to 64% of free cash flow. Free cash flow covered dividend payments 4.7 times.
Summary generated from market data by MetaCap's automated system. Methodology
ResMed cash flow statement (annual)
| Fiscal year (USD) | FY 20262026-06-30 | FY 20252025-06-30 | FY 20242024-06-30 | FY 20232023-06-30 | FY 20222022-06-30 | FY 20212021-06-30 | FY 20202020-06-30 | FY 20192019-06-30 | FY 20182018-06-30 | FY 20172017-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 1.52B | 1.40B | 1.02B | 897.56M | 779.44M | 474.50M | 621.67M | 404.59M | 315.59M | 342.28M |
| Net Income growth (YoY) | +8.75% | +37.20% | +13.75% | +15.15% | +64.26% | -23.67% | +53.65% | +28.20% | -7.80% | -2.87% |
| Depreciation & Amortization | 201.34M | 198.47M | 176.87M | 165.16M | 159.61M | 156.76M | 154.85M | 150.79M | 119.96M | 112.16M |
| Stock-Based Compensation | 104.35M | 91.66M | 80.18M | 71.14M | 65.26M | 63.93M | 57.56M | 52.07M | 48.41M | 45.92M |
| Change in Working Capital | -74.24M | 16.74M | 44.78M | -462.13M | -708.08M | 1.41M | -97.92M | -177.05M | 9.06M | -89.88M |
| Operating Cash Flow | 1.81B | 1.75B | 1.40B | 693.30M | 351.15M | 736.72M | 802.25M | 459.05M | 505.03M | 414.05M |
| Capital Expenditures | -156.28M | -89.86M | -99.46M | -119.67M | -134.84M | -102.71M | -95.33M | -68.71M | -62.58M | -62.22M |
| Investing Cash Flow | -545.20M | -200.04M | -269.78M | -1.16B | -229.92M | -158.46M | -179.86M | -1.08B | -101.82M | -81.89M |
| Dividends Paid | -349.66M | -310.88M | -282.32M | -258.28M | -245.34M | -226.71M | -225.09M | -211.71M | -199.50M | -186.35M |
| Share Repurchases | -700.04M | -300.02M | -150.01M | 0 | 0 | — | — | -22.84M | -53.80M | — |
| Debt Issued | 0 | 0 | 105.00M | 1.07B | 288.00M | 90.00M | 1.19B | 1.52B | 350.00M | 450.00M |
| Debt Repaid | -10.00M | -40.00M | -835.00M | -405.00M | -166.00M | -612.00M | -1.28B | -711.75M | -1.15B | -545.00M |
| Financing Cash Flow | -1.01B | -606.25M | -1.12B | 422.87M | -128.36M | -764.63M | -317.29M | 580.64M | -1.03B | -262.87M |
| Net Change in Cash | 259.78M | 971.09M | 10.47M | -45.82M | -21.57M | -167.88M | 316.03M | -41.57M | -633.23M | 90.50M |
| Free Cash Flow | 1.65B | 1.66B | 1.30B | 573.63M | 216.31M | 634.01M | 706.92M | 390.34M | 442.44M | 351.83M |
This table shows 10 annual periods of ResMed's cash flow statement, from FY 2026 back to FY 2017, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow RMD's reporting calendar. What is a cash flow statement?